Suggested remit: To appraise the clinical and cost effectiveness of canakinumab within its marketing authorisation for treating Schnitzler syndrome.
 
Status Topic selection
Technology type Medicine
Decision Not selected
Reason for decision Not eligible for Health Technology Evaluation guidance
Further information The NICE Topic Selection Oversight Panel (TSOP), met in September 2022 to carefully consider the suitability of this topic for a Technology Appraisal (TA). The panel concluded it would not be an efficient use of NHS resources to conduct an evaluation. The topic will be formally removed from the NICE work programme.
ID number 4063

Project Team

Project lead Michelle Adhémar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
09 November 2022 Topic selection. .
24 August 2022 (10:00) Scoping workshop
07 July 2022 - 04 August 2022 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
07 July 2022 In progress. Scoping commenced
03 March 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected
15 February 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on how we select topics for development, please see our page about topic selection